Coronary Artery Disease - patients with chronic stable angina Circulatory System Coronary Artery Disease
Conditions
Interventions
Drug: allopurinol 300 mg - 600 mg given for six weeks.
Allopurinol (the intervention drug) is given orally (p.o.). Starting dose is 100 mg once daily (od). This is escalated over two weeks to a maxi
Sponsors
University of Dundee (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Documented Coronary artery Disease (CAD) on angiography 2. Chronic stable angina (greater than two months) 3. Able to do Exercise Treadmill Test (ETT) 4. Aged between 30 and 85 years
Exclusion criteria
Exclusion criteria: 1. Contra-indication or unable to do ETT 2. Already on allopurinol or previous allergy to allopurinol 3. Left Ventricular (LV) ejection fraction less than 45% 4. Myocardial Infarction (MI) or Acute Coronary Syndrome (ACS) over the last two months 5. Change to anti-anginal therapy over the last month 6. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG) within the last six months 7. Significant renal or hepatic impairment 8. On medication that may interact with allopurinol (e.g., warfarin)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to ST depression on ETT. Outcomes will be assessed at the start and every six weeks (at the end of each treatment period - allopurinol or placebo). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Total exercise time 2. Time to symptom on ETT 3. Assessment of angina 4. Measurement of C-Reactive Protein (CRP), B-type Natriuretic Peptide (BNP) and Procollagen III N-terminal Peptide (PIIINP) Outcomes will be assessed at the start and every six weeks (at the end of each treatment period - allopurinol or placebo). | — |
Countries
United Kingdom
Outcome results
None listed